EffRx Pharmaceuticals SA

Alkindi

Alkindi®

Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenocortical insufficiency (AI). Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone granules in capsules for opening which allows accurate age-appropriate dosing in particular infants and children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from pediatric AI and the related condition congenital adrenal hyperplasia (CAH).

Alkindi® is already approved and marketed in the European Union as well as in the USA. EffRx has an exclusive license agreement with Diurnal Group plc, a listed UK-headquartered specialty pharmaceutical company, for the registration and commercialization of Alkindi® in Switzerland.

EffRx has obtained the Swiss Marketing Authorization for Alkindi® as a replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to less than eighteen years) at the end of 2020.

EffRx expects Alkindi® to be available on the Swiss market by mid-June 2022. In Switzerland, there are approximately 200 patients suffering from pediatric AI.